Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Saved in:
Bibliographic Details
Title: Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.
Authors: Papi A; Pulmonary Division, University of Ferrara, St Anna University Hospital, Ferrara, Italy. Electronic address: ppa@unife.it., Greening NJ; Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK., Bhatt SP; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Roche N; Université Paris Cité, APHP Centre, Hôpital et Institut Cochin, Paris, France., Celli B; Mass General Brigham Hospital, Harvard University Medical School, Boston, MA, USA., Wedzicha JA; National Heart and Lung Institute, Imperial College London, London, UK., Agustí À; University of Barcelona, Barcelona, Spain; Respiratory Institute, Hospital Clinic, Barcelona, Spain; FCRB-IDIBAPS, Barcelona, Spain; CIBER Enfermedades Respiratorias, ISCIII, Spain., Tal-Singer R; Global Allergy & Airways Patient Platform, Vienna, Austria., Han MK; University of Michigan, Ann Arbor, MI, USA., Janssens W; Department of Chronic Diseases and Metabolism (CHROMETA), University Hospital Leuven, KU Leuven, Belgium., Hanania NA; Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA., Nair P; Department of Medicine, McMaster University, Hamilton, ON, Canada; Research Institute of St Joe's Hamilton, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada., Bremner P; University of Notre Dame, Fremantle, WA, Australia., Porpodis K; Pulmonology Department, G Papanikolaou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece., Shibata Y; Fukushima Medical University, Fukushima, Japan., Korn S; IKF Pneumologie Mainz, Mainz, Germany; Thoraxklinik Heidelberg, Heidelberg, Germany., Yang T; China-Japan Friendship Hospital, Beijing, China., Gordon O; Roche Products, Welwyn Garden City, Hertfordshire, UK., Saenz R; Genentech, South San Francisco, CA, USA., Ng J; Genentech, South San Francisco, CA, USA., Cheung DS; Genentech, South San Francisco, CA, USA., Devine J; Genentech, South San Francisco, CA, USA., Grimbaldeston MA; Genentech, South San Francisco, CA, USA., Zhang W; Genentech, South San Francisco, CA, USA., Yang X; Genentech, South San Francisco, CA, USA., Mohan D; Genentech, South San Francisco, CA, USA., Vogelmeier CF; Department of Medicine, Pulmonary, Critical Care and Sleep Medicine, Philipps University of Marburg, German Center for Lung Research (DZL), Marburg, Germany., Brightling CE; Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Corporate Authors: ALIENTO and ARNASA investigators
Source: Lancet (London, England) [Lancet] 2026 May 23; Vol. 407 (10543), pp. 2027-2039. Date of Electronic Publication: 2026 May 18.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(26)00637-9